Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.
In the latest development in the race for an Ebola vaccine, Merck and partner NewLink have taken their candidate to late-stage trials in Sierra Leone, the companies announced Tuesday.
Thanks to a big stock grant, Merck & Co.'s Kenneth Frazier vaulted to the highest echelons of pharma CEO pay last year. With a pay package valued at more than $25 million, Frazier beat out Pfizer's Ian Read and Johnson & Johnson's Alex Gorsky--even if he fell far short of Regeneron chief Len Schleifer.
When Roger Perlmutter exited an early "retirement" from Amgen to join Merck as head of R&D two years ago, he was going back to a company with one of the weakest R&D records in Big Pharma. One of his first chores was to execute a major restructuring, aimed at slimming down the pharma giant's multibillion-dollar R&D budget. And he simultaneously hit the accelerator on the PD-1 drug Keytruda, which won a pioneering FDA OK last year.
Merck put two of three plants in Puerto Rico on a hit list in 2013 as part of its efforts to cut costs and headcount. But after selling one last year to Sanofi's animal health unit Merial, it has found a buyer for the second, efforts that together will have saved about 400 jobs on the island.
An outbreak of canine influenza in the Chicago area has affected 1,000 dogs, 5 of which died. The Cook County Department of Animal and Rabies Control is recommending that dog owners there obtain the canine influenza vaccine, which is made by Merck Animal Health.
Think we've seen a hepatitis C drug price war? Think again. This first round of pay-to-play formulary deals may pale in comparison to what's coming next year, as Merck & Co. gets closer to launching its two-drug combo pill.
Merck execs weren't happy when the FDA stripped its breakthrough therapy designation for their closely watched hepatitis C combo. But the agency has now relented--at least partly. The pharma giant said it's getting two new BTD titles in small subgroups of patients to replace the broader breakthrough tag that it lost.
The FDA notified Merck execs last January that it was stripping away its breakthrough therapy designation for their closely watched hepatitis C combo. But the agency has now relented and reversed itself, in part, and the pharma giant today notes that it's getting two new BTD titles in narrow patient subpopulations to replace the broader one that it lost.
Merck has partnered up with fast-moving upstart Arvinas to get its hands on technology that promises to give drug developers a crack at some previously untouchable targets, using the body's natural garbage system to dump troublesome proteins.